Similar articles

• In vitro susceptibility of aerobic gram-negative blood culture isolates to oxolinic acid, norfloxacin, ciprofloxacin, enoxacin, pefloxacin, ofloxacin and oxo-enoxacin.

  Van der Auwera P. Van der Auwera P. Infection. 1986 May-Jun;14(3):142-4. doi: 10.1007/BF01643481. Infection. 1986. PMID: 2942489
• [In vitro activity of new quinolones against Mycoplasma pathogenic to humans].

  Renaudin H, Quentin C, de Barbeyrac B, Bebear C. Renaudin H, et al. Pathol Biol (Paris). 1988 May;36(5):496-9. Pathol Biol (Paris). 1988. PMID: 3136430 French.
• Clinical uses of nalidixic acid analogues: the fluoroquinolones.

  Høiby N. Høiby N. Eur J Clin Microbiol. 1986 Apr;5(2):138-40. doi: 10.1007/BF02013968. Eur J Clin Microbiol. 1986. PMID: 3013628 No abstract available.
• Quinolones in the treatment of serious infections.

  Webster A, Gaya H. Webster A, et al. Rev Infect Dis. 1988 Jan-Feb;10 Suppl 1:S225-33. doi: 10.1093/clinids/10.supplement_1.s225. Rev Infect Dis. 1988. PMID: 3279496 Review.
• The fluoroquinolones: pharmacology, clinical uses, and toxicities in humans.

  Hooper DC, Wolfson JS. Hooper DC, et al. Antimicrob Agents Chemother. 1985 Nov;28(5):716-21. doi: 10.1128/AAC.28.5.716. Antimicrob Agents Chemother. 1985. PMID: 2936302 Free PMC article. Review. No abstract available.